MPDL3280A Immunotherapy Doubles OS in Non-Small Cell Lung Cancer Patients with Highest Levels of PD-L1

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Interim results from a global, randomized phase II study in people with previously treated non-small cell lung cancer showed that the immunotherapy MPDL3280A doubled the overall survival (HR=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login